Regulatory Filings Accepted for Perioperative Nivolumab Plus Chemotherapy in NSCLC

The FDA and EMA have accepted applications seeking the approval of neoadjuvant nivolumab/chemotherapy followed by surgery and adjuvant nivolumab in NSCLC.

Related Keywords

United States ,America ,Abderrahim Oukessou ,European Medicines Agency ,Bristol Myers Squibb ,Prescription Drug User Fee ,North America ,Fda ,Fema ,Nivolumab ,Nsclc ,Adjuvant Nivolumab ,Opdivo ,Nivolumab Plus Chemotherapy ,